Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P
Medtronic, Inc. · Decision date Oct 29, 2026
What did the FDA decide?
The FDA record for P010015/S592 lists Medtronic, Inc. as applicant and describes the supplement's stated purpose as a series of battery electrolyte fill manufacturing process updates at Medtronic Energy and Components Center. The supplement type is a 30-Day Notice with reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The listed products are Percepta and Serena bipolar and quadripolar CRT-P devices and Solara bipolar CRT-P, under product code LWP.
The statement identifies a manufacturing-process update at a named supplier site but does not specify which update, the equipment or steps affected, or how these relate to the listed CRT-P models. The decision code is OK30, dated 2026-10-29. The P010015 identifier ties the notice to that PMA file; it is not a new approval of those devices, and the notice does not itself show safety or clinical effectiveness.
FDA approval order statement
a series of battery electrolyte fill manufacturing process updates at Medtronic Energy and Components Center
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 29, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P010015/S592
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- LWP
- Decision code
- OK30
- Decision date
- Oct 29, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implantable pulse generator, pacemaker (non-CRT).
- Applicant
- Medtronic, Inc.
- Product code
- LWP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P010015. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010015 · Original PMA
MEDTRONIC INSYNC(TM) BIVENTRICAL PACING SYSTEM
P010015/S590 · Related supplement
Percepta Bipolar CRT-P, Percepta Quadripolar CRT-P, Serena Bipolar CRT-P, Serena Quadripolar CRT-P, Solara Bipolar CRT-P
P010015/S592 received
Application receipt date recorded by FDA.
P010015/S591 · Related supplement
Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1TR02); Serena Quadripolar
P010015/S592 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P010015. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010015
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA approval | Aug 28, 2001 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 5, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Explore the linked device profile
Other records with product code LWP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Boston Scientific Corp | PMA supplement | Oct 3, 2026 | FDA | |
| Boston Scientific | PMA supplement | Oct 3, 2026 | FDA | |
| Boston Scientific | PMA approval | Apr 25, 2016 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. N.E, Ms Mvs11, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P010015/S592
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

